All In Biotech

Drug Trial Radar · NCT00679965

Study of Different Doses of a Novel Treatment for Onychomycosis

A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 2.5%, 5.0%, and 7.5% Solutions vs. Vehicle for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail

Last checked: Nov 20, 2026Latest source record: Dec 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 159 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

159

Actual

Start

Feb 28, 2006

Primary completion

Jul 31, 2007

Study completion Jul 31, 2007

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 19, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine the safety and efficacy of 2.5%, 5.0%, and 7.5% AN2690 Solutions compared to the vehicle alone in the treatment of distal, subungual onychomycosis of the great target toenail.

Conditions

  • Distal, Subungual Onychomycosis

Interventions

  • AN2690, 2.5%Drug

    Once daily application for 90 days and 3 x weekly for 90 days

  • AN2690, 5%Drug

    Once daily application for 90 days and 3 x weekly for 90 days

  • AN2690, 7.5%Drug

    Once daily application for 90 days and 3 x weekly for 90 days

  • AN2690 Solution VehicleDrug

    Once daily application for 90 days and 3x weekly for 90 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical evidence of complete great toenail clearance or at least fungal-clear great toenail growth ("complete" = 5mm; "partial" = 2mm), plus a negative fungal culture from the treatment-targeted great toenail.Time frame: Day 180

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Unidad de Investigación en Salud (UIS)

    Chihuahua City, Mexico

  • Hospital "Dr. Angel Leaño"

    Guadalajara, Mexico

  • Instituto Dermatologico Jalisciense

    Guadalajara, Mexico

  • Centro Dermatologico Pascua

    Mexico City, Mexico

  • CIF-BIOTEC Medica Sur.

    Mexico City, Mexico

  • IMIC

    Mexico City, Mexico

  • Hospital Universitario Dr. José Eleuterio González

    Monterrey, Mexico

  • MIRC / OCA Hospital

    Monterrey, Mexico

  • ISSEMYM

    Toluca, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.